Abiopharma

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

Trevi Therapeutics to Participate in Upcoming August Conferences

New Form 144 - UroGen Pharma Ltd. Filed: 2025-07-29 AccNo: 0001976408-25-000249 Size: 4 KB

New Form 144 - UroGen Pharma Ltd. Filed: 2025-07-29 AccNo: 0001976408-25-000248 Size: 4 KB

New Form 10-Q - uniQure N.V. Filed: 2025-07-29 AccNo: 0001558370-25-009694 Size: 8 MB

New Form 10-Q - NEOGENOMICS INC Filed: 2025-07-29 AccNo: 0001077183-25-000154 Size: 7 MB

New Form 8-K - GeneDx Holdings Corp. Filed: 2025-07-29 AccNo: 0001818331-25-000105 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Q2 2025 Energous Investor Update

New Form 6-K - Concord Medical Services Holdings Ltd Filed: 2025-07-29 AccNo: 0001104659-25-071402 Size: 11 KB

New Form 6-K - Grifols SA Filed: 2025-07-29 AccNo: 0001104659-25-071400 Size: 42 KB

Evogene Schedules Second Quarter 2025 Financial Results Release

New Form 8-K - uniQure N.V. Filed: 2025-07-29 AccNo: 0001558370-25-009692 Size: 307 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits